University of Dundee

Community-acquired pneumonia related to intracellular pathogens

Cillóniz, Catia; Torres, Antoni; Niederman, Michael; van der Eerden, Menno; Chalmers, James; Welte, Tobias

Published in:
Intensive Care Medicine

DOI:
[10.1007/s00134-016-4394-4](https://doi.org/10.1007/s00134-016-4394-4)

Publication date:
2016

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Cillóniz, C., Torres, A., Niederman, M., van der Eerden, M., Chalmers, J., Welte, T., & Blasi, F. (2016). Community-acquired pneumonia related to intracellular pathogens. *Intensive Care Medicine*, 42(9), 1374-1386. <https://doi.org/10.1007/s00134-016-4394-4>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Community- Acquired Pneumonia Related to Intracellular Pathogens

Catia Cillóniz¹, Francesco Blasi², James Chalmers³, Menno van der Eerden⁴, Tobias Welte⁵, Michael Niederman⁶; Antoni Torres¹,

¹Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB) - SGR 911- Ciber de Enfermedades Respiratorias (Ciberes) Barcelona, Spain.

² Department of Pathophysiology and Transplantation, Università degli Studi di Milano, IRCCS Fondazione Ospedale Maggiore Policlinico Cà Granda, Milan Italy

³ Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK

⁴ Department of Pulmonary diseases, Erasmus Medical Centre, Rotterdam, The Netherlands

⁵ Department of Pulmonary Medicine, Hannover Medical School and Member of the German Center of Lung Research (DZL), Hannover, Germany.

⁶ Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York City, New York, USA.

Corresponding author:

Antoni Torres

Department of Pneumology, Hospital Clinic of Barcelona

Phone +34932275549/ Fax +34932275549

Email: atorres@clinic.ub.es

Introduction

Community-acquired pneumonia (CAP) is associated with high rates of morbidity and mortality worldwide^{1;2}; annual CAP incidence among adults in Europe has ranged from 1.5 to 1.7 per 1,000 populations. CAP varies from a mild outpatient illness to a more severe disease requiring hospitalization, and among hospitalized patients, approximately 10% required admission to an intensive care unit (ICU)³.

Intracellular bacteria are common causes of CAP^{4;5} (Figure 1). However, there is a wide variation in the reported incidence, depending in part on the difficulties with microbiological culture, because they grow poorly in standard culture media and culture requires expertise. The new development of molecular microbiological techniques should help to clarify the epidemiology and presentation of intracellular pathogens in CAP and help a shift to more targeted antimicrobial therapy⁶. The intracellular pathogens that are well-established as causes of pneumonia are: *Legionella pneumophila*, *Mycoplasma pneumoniae*, *Chlamydomphila pneumoniae*, *Chlamydomphila psittaci* and *Coxiella burnetii*⁷.

Although extra-pulmonary manifestations are often associated with these pathogens in pneumonia, no clinical features allow them to be reliably distinguished from classical bacterial agents of pneumonia such as *Streptococcus pneumoniae* (pneumococcus)⁸ mainly in patients who need hospitalization. Due to the fact that these bacteria are naturally resistant to β -lactams, they should be promptly identified. Macrolide and quinolones remain the best empirical treatment of intracellular pathogens, because of their good antimicrobial activity and high intracellular concentrations. Although, antibiotic resistance in these intracellular pathogens does

not currently represent a clinical problem in the majority of settings, recent studies from Asia and some European countries report about isolation of strains of *M. pneumoniae* resistant to macrolides, suggest a need to monitor these pathogens to evaluate the clinical impact of resistance in CAP^{9;10}.

These microorganisms in approximately 1% to 7% might cause severe CAP¹¹⁻¹³.

Epidemiology and Clinical features

Legionella pneumophila

Legionella pneumophila is a Gram-negative intracellular bacillus that causes the majority of clinical cases of severe pneumonia termed Legionnaires' disease (LD). *Legionella* is responsible for summer to autumn outbreaks, and is an important cause of community acquired pneumonia and hospital acquired pneumonia^{6;14}. Pneumonia caused by *L. pneumophila* is indistinguishable by clinical and radiographic features from other pneumonias caused by "typical" pathogens such as pneumococcus.

In Europe and in the USA *L. pneumophila* serogroup 1 causes the vast majority of *Legionella* pneumonia, accounting for approximately 85% of cases¹⁵. However, *L. longbeachae* is the specie reported in approximately 25% of the pneumonia cases in countries such as Australia, Scotland, Thailand and New Zealand¹⁶⁻¹⁸.

LD is rare in children; the majority of reported cases occur in people ≥50 years and cases are predominantly in male patients¹⁹ (Figure 2). The principal risk factors for LD are: current smoker (compromises mucociliary clearance), current alcohol consumer, diabetes, chronic obstructive disease and immunosuppression. Epidemiology of LD is well recorded because it is notifiable disease. In 2014, a total of

6, 941 cases of LD were reported by 28 EU Member States and Norway²⁰. Five countries (France, Italy, Spain, Germany, and Portugal) accounted for 74% of all notified cases (Figure 3). Most cases were community acquired (74%), 18% were travel-associated, and 7% were linked to healthcare facilities. People over 50 years of age accounted for 80% of all cases. The male-to-female ratio was 2.6:1. The case-fatality ratio was 8% in 2014, similar to previous years. Most cases (87%) were confirmed by urinary antigen test, but an increasing proportion of cases are reported to have been diagnosed by PCR. *L. pneumophila* serogroup 1 was the most commonly identified pathogen, accounting for 81% of culture-confirmed cases²⁰.

Woodhead *et al*²¹. in a study published in 2002, suggested a frequency of *Legionella* spp. in ICU patients of 7.9%. Similar data were reported in 2011 from Spain, showing 8% of ICU patients with CAP had infection with *L. pneumophila*¹². Nevertheless, the recent article by Jain *et al*¹¹. concerning the etiology of pneumonia in the community (EPIC) study, report that *L. pneumophila* was present in 1% of the ICU patients with defined microbial etiology. In USA the CDC estimates that between 8,000 to 18,000 people are hospitalized with LD each year and approximately 5 to 30% of these patients die²². Welte *et al*²³. in a review article included 46 CAP studies from 13 European countries, observed a frequency of *Legionella* spp. in 12% of the ICU CAP cases. Nowadays, with improved detection methods, including urinary antigen test, more cases are being identified and many more mild cases than in the past are being recognized.

LD can present as a severe pneumonia that may be accompanied by systemic symptoms such as fever, diarrhoea, myalgia, impaired renal and liver functions, and delirium. LD is also frequently associated with hyponatraemia, dry cough, elevated

lactate dehydrogenase and markedly elevated C-reactive protein levels and platelet count. Although none of these features are specific for LD, Haubitz clearly demonstrated that in the absence at least 2 of these factors, LD was excluded with 99% accuracy ²⁴. In patients with risk factor (smoking, chronic cardiovascular or respiratory disease, diabetes, alcohol abuse, and immunosuppression) LD sometimes is complicated with more severe disease (cavitation and pleural effusions)²⁵⁻²⁹. Jacobson et al³⁰. reported in a study of *Legionella* pneumonia in cancer patients the presence of multilobar pneumonia in 82% of the patients, bilateral involvement in 80% and pleural effusion in 56% of the patients.

Mycoplasma pneumoniae

M. pneumoniae is a common cause of CAP in adults^{12;15;31}. *M. pneumoniae* have a single triple- layered membrane and lacks a cell wall structure; this characteristic makes this microorganism insensitive to β -lactams antibiotics.

When an individual has active infection with *M. pneumoniae* it is possible to recover viable bacteria from the nose, throat, trachea and sputum samples. The incidence of *M. pneumoniae* CAP is lower in elderly patients compared with young adults³². The study by Dumke et al⁶. showed that *M. pneumoniae* was more common in younger patients, more frequent in females and patients with fewer comorbid conditions than CAP from other causes (Figure 4). Pneumonia caused by *M. pneumoniae* presented with frequent extrapulmonary manifestations (encephalitis, optic neuritis, acute psychosis, stroke, cranial nerve palsies and aseptic meningitis)^{33;34}. In CAP *M. pneumoniae* accounts for up to 37% of the patients treated as outpatients and 10% of patients that required hospitalization^{35;36}. In a few cases, pneumonia caused by *M. pneumoniae* developed into refractory or severe pneumonia^{37;38}. Miyashita et al³⁷.

reported in a study of severe *M. pneumoniae* in ICU patients, that 6% of the 227 patients with *Mycoplasma* infection were admitted to ICU because acute respiratory failure. In a review of 52 cases of fulminant *M. pneumoniae* pneumonia from Japan, the authors observed that the dominant population of fulminant *M. pneumoniae* pneumoniae was young adults without severe underlying diseases. The major clinical manifestation was respiratory failure with diffuse abnormal findings in radiological examinations.³⁸.

There are recent reports from Asia and some European countries describing the isolation of strains of *M. pneumoniae* resistant to macrolide^{9;10}. The clinical relevance of macrolide resistance of *M. pneumoniae* in CAP cases is still under debate, but some studies suggest that severity of the disease and clinical manifestations in adults are similar in patients with susceptible strains who are receiving treatment^{39;40}. More studies are needed to understand the clinical significance of macrolide-resistance *M. pneumoniae* in adults with CAP.

Chlamydophila pneumoniae* and *Chlamydophila psittaci

C. pneumoniae is endemic globally, and has a unique life cycle where this intracellular bacteria expresses different phenotypes that permits to survival for many years into a phase of rest that allow it to cause persistent infection.

The incubation period is around 21 days; approximately 50% of young adults and 75% of elderly persons have serologic evidence of a previous infection. The clinical course infection with *C. pneumoniae* may vary from sub clinical to mild and, more rarely, to severe pneumonia. Outcome of the patients is directly related to immune competence. Risk for infection and persistence are advanced age, current smoking,

male gender, glucocorticoid use, and residence in a long-term care facility. Up to 20% of CAP in adults is reported to be caused by *C. pneumoniae*^{12;41}. The majority of this study is based on serology, and the relationship between positive *C. pneumoniae* serology and CAP aetiology is debated. Cillóniz et al¹² found only 3% are caused by *C. pneumoniae*. Chalmers et al.⁴² found a maximum of 2.2% of CAP caused by *C. pneumoniae*. The study of Arnold et al¹⁵, showed that the incidence of CAP due *C. pneumoniae* from 4,337 patients was: North America 8%, Europe 7%, Latin America 6% and Asia 5% . Respiratory infections caused by *C. pneumoniae* are often asymptomatic but in approximately 10% of adolescent and young adults develop a mild disease⁴³. Sore throat with hoarseness is often severe and may precede pneumonia by up to a week and resolve before pneumonia onset, resulting in a biphasic illness.

Common symptoms of *C. psittaci* infection include abrupt onset of fever, chills, headache, myalgia, non-productive coughing and dyspnea. Radiographic findings may include lobar or interstitial infiltrates. In some cases there are complications such as pericarditis, endocarditis or myocarditis, hepatomegaly and splenomegaly⁴⁴. Persons exposed to infected birds are at risk for infection with *C. psittaci*, and this disease is found worldwide with approximately 70% of the cases having a known source of infection as a result of exposure to pet birds⁴⁵.

Mortality rate related to *C. pneumoniae* infection is low. However, if the first upper respiratory signs associated with *C. pneumoniae* infection is not treated; severe disease or even death may result⁴⁴. The diagnosis of psittacosis can be difficult, and many more cases may occur that are not correctly diagnosed or reported.

Coxiella burnetii

Infection in humans by *C. burnetii* often is asymptomatic or presents as an influenza-like illness or atypical pneumonia with patchy pulmonary infiltrates that are recognized as the most common form of presentation in acute Q fever⁴⁶.

C. burnetii is an obligate intracellular Gram-negative bacterium. Pneumonia caused by *C. burnetii* is generally mild but progression to acute respiratory distress syndrome (ARDS) can occur⁸. European countries such as the UK^{47;48}, France, Greece, Spain and the Netherlands^{49;50} have reported important outbreaks. In the USA, surveillance studies from 2000 to 2012, reported an incidence of 0.38 cases per million persons/ year, with a mortality rate of 2% and a 62% of rate of hospitalizations⁵¹.

A German study published in 2014 reported a high prevalence of Q fever as CAP (3.5%) in the summer of 2005 in Germany⁵². In 2007, a major epidemic occurred in the general population in the Netherlands which resulted in approximately 2,300 reported cases. An epidemiologic explanation for this outbreak was a possible spatial link between dairy goat farms and human cases⁵³. Wielders et al⁵⁴. describe epidemiological and clinical features of 183 hospitalized acute Q fever patients. Pneumonia was development in 86% of patients, 4% were admitted to the ICU and the mortality rate in general was 6%.

It was reported that Q fever is most frequent in males. In Australia and France, males are 5-fold and 2.5-fold more likely than females to develop disease, respectively⁵⁵.

Co-infection with other pathogens

The study by Cillóniz et al⁵⁶. included 362 adult patients with CAP admitted to the ICU, identified that 10% of the CAP cases with defined microbial etiology were caused by

intracellular pathogens. Co-infection of intracellular pathogens and other microorganism were observed in 30% of the cases caused by intracellular pathogens.

Pathogenesis

The principal characteristics of intracellular pathogens are that they are able to grow and reproduce inside the cells of their host. This characteristics help to these pathogens evade the host immune system. Antimicrobial treatment for these pathogens is very challenging because many antimicrobials are unable to access intracellular spaces and achieve the optimum therapeutic concentrations within the infected cells.

Legionella pneumophila

L. pneumophila grows into lung macrophages after aerosols are inhaled from contaminated water sources. A recent published letter reported a probable person-to-person transmission of LD; the authors described two cases of LD. The patients were relatives (mother and son) and the factors that suggest person-to-person transmission are: The severity of the respiratory symptoms, 8 hours of close contact between the two patients, the small area of the non-ventilated room where the contact took place⁵⁷.

L. pneumophila multiplies intracellularly until the cell ruptures, then infects other macrophages. *L. pneumophila* have virulence factors that potentiate the infection of macrophages and inhibit phagosomal fusion avoiding macrophage cell death pathways and promoting bacterial survival therefore allowing sufficient time for replication. When *L. pneumophila* establishes infection, this intracellular bacteria causes a fibrino-

purulent pneumonia. Hepatic involvement is commonly manifested by mildly increased serum transaminases in *Legionella* CAP.

Mycoplasma pneumoniae

This microorganism is transmitted by aerosols from person to person. In general the incubation period varies from 1 to 3 weeks. Approximately 3% - 4% of patients with *M. pneumoniae* pneumonia develop severe CAP associated a respiratory failure and acute respiratory distress syndrome (ARDS). The study of Nilsson et al⁵⁸. showed that the severity of *M. pneumoniae* seems to depend on *M pneumoniae* bacterial load rather than *M pneumoniae* genotype (MP1 or MP2). Other studies associated the delayed administration of adequate antimicrobials with severe *M. pneumoniae* pneumonia^{37;38}. Pathogenicity of *M. pneumoniae* depends on its attachment to respiratory epithelium and initiation of injury to the host. The study of Jiang et al.⁵⁹ showed the association between abnormalities in ciliated respiratory epithelium with severity of *M. pneumoniae* infection.

The principal virulence factors in *M. pneumoniae* are related to hydrogen peroxide production, lipoproteins and more recently reported CARDS toxin (ADP-ribosylating and vacuolating cytotoxin)⁶⁰ that exhibits similarities with pertussis toxin.

In addition to these virulence factors, the emergence of macrolide-resistant *M. pneumoniae* strains^{40;61;62} (by point mutations in the 23S RNA gene³³) and the frequency of extrapulmonary complications (neurological, cardiac, dermatological, musculoskeletal and haematological) reported make treatment more difficult⁶³. It is known that this development is associated with an active immune response to the pathogen and excessive expression of cytokines such as IL- 18, which was

demonstrated in the case-control study of pneumonia caused by *M. pneumoniae* published by Tanaka et al⁶⁴

Chlamydophila pneumoniae

C. pneumoniae has a specific tropism and exhibits cytotoxic activity towards the airway epithelium, in which it proliferates and destroys infected cells by lysis.

Co-infection with other respiratory pathogens may play an important role ⁶⁵ in approximately 30% of adult patients with CAP.

C. pneumoniae need neutrophil granulocytes cells to live and multiply, however these cells have a short life span. The inhibition of neutrophil apoptosis by *C pneumoniae* appears to play a major role in the production of infection of these cells by *C. pneumoniae*.

Coxiella burnetii

The principal reservoirs of infection are farm and domestic animals, especially sheeps and goats. Infection of humans is mainly through inhaling contaminated aerosols, which occurs mainly during and several weeks after labour of goats and sheeps. This bacterium is resistant in the environment and it may survive for long time periods in dust and fecal particles. The period of incubation varies from 7 to 40 days with an average of 21 days ^{66;67}.

The target cells for *C. burnetii* infection are monocytes and macrophages. *C. burnetii* lives inside phagosome with special acid characteristics that allow this pathogen to receive nutrients and to resist antibiotics⁶⁸. It is known that lipopolysaccharide (LPS) is the main virulence factor of *C. burnetii* infection. Development of infection is related to host comorbidities and cell-mediate immunity.

Microbiological Diagnosis

Intracellular pathogens are difficult to culture and isolated. The general microbiological assays to diagnose these pathogens are: antigen detection, molecular assays such as PCR and serology. Sputum, bronchoalveolar lavage, bronchoalveolar aspirate and pleural fluid are the principal samples for the diagnosis of these pathogens (Figure 5).

Culture

Culture of *M. pneumoniae* is the reference diagnostic test for this pathogen but is rarely performed. The principal limitation is that it is expensive and time-consuming (almost 10 days), requires specialized media, technical expertise and is not available except in reference laboratories. The sensitivity is 60% and specificity 100%.

Culture of respiratory samples in buffered charcoal yeast extract agar (BCYE) is the gold standard method for diagnosis of *L. pneumophila*. Isolation of the strains involved in the infection allows epidemiological typing, which provides valuable data for the control and prevention of further cases. Sensitivity of *Legionella* culture varies widely ranging from 50% - 80%^{69;70}. In cases of severe CAP the sensitivity is higher because of the higher microbial load in respiratory samples.

C. burnetii is a pathogen with high infectivity, dangerous and difficult to isolate. Culture of this pathogen is performed on human erythroleukaemia cells (HEL cells) over 5 to 7 days, or it is possible to observe *C. burnetii* by microscopy after immunofluorescence staining⁷¹.

Antigen Detection

Diagnosis of *L. pneumophila* is made most frequently through detection of *Legionella* antigen in urine (urinary antigen test), the sensitivity of this test is approximately 70% with specificity of 95%⁷². The principal problem with this assay is that it is only

diagnostic for *L. pneumophila* serogroup 1 can we identified, which is the most frequent serogroup involved in CAP cases. The antigen of *Legionella* can persist in urine for weeks and months following infection.

Also the direct immunofluorescence assay in sputum samples, respiratory secretions or pleural fluid is an easy way to diagnose *Legionella*, with a sensitivity ranging from 33% to 68% and a specificity of 95%, but the principal obstacle is to collect a good quality sample.

Serology

Serology is the main diagnostic assays for *M. pneumoniae*, *C. pneumoniae*, *C. psittacii* and *C. burnetii*. However the lack of specificity due to a possible cross reactivity with other microorganisms is a major limitation. Also, IgM and IgG may take 6 – 8 weeks to appear, Requiring collection of both acute and convalescent titers.

An acutely elevated IgM titer for *M pneumoniae* or *C. pneumoniae* in a patient with CAP is considered diagnostic. While a four- fold increase in IgG titer is indicative of past exposure or infection by *M pneumoniae* or *C pneumoniae*.

In the case of *C. burnetii*, persistently highly elevated IgG levels indicate chronic Q fever rather than acute infection.

Molecular diagnosis (PCR)

Molecular techniques such as PCR or multiplex PCR are of use for identification of intracellular pathogens (*M. pneumoniae*^{73;74}, *C. pneumoniae*, *C. psittaci*, *C. burnetii*) in CAP. These new techniques can also help to identify the infectious strains of these problematic pathogens.

Although, serology is the main diagnostic test for *C pneumoniae* and *C psittaci*, this is not well standardized, and PCR is emerging as a rapid sensitive mode of detection⁷⁵.

PCR in blood samples or serum provides a rapid and definitive diagnosis of *C. pneumoniae*. Also culture of infected tissue is an option, however it requires special facilities. PCR in sputum samples has greater sensitivity (80%) and specificity (90%) for the detection of *Legionella* and also has the possibility to detect other species such as *L. longbeachae*⁷⁶.

Molecular assays will help in the early diagnosis of chronic and acute Q fever⁷⁷. In the last few years several molecular assays were developed to detect the DNA of *C. burnetii* in clinical samples and in cell culture.

Antibiotic Treatment

The selection of empiric antibiotic treatment of CAP generally is based on possible risk factors for specific pathogens and the knowledge of local antimicrobial resistance. Therefore, in moderate to severe cases it is recommended that empiric antibiotic treatment should covering typical and atypical (intracellular) pathogens.

Legionella pneumophila

Azithromycin and fluoroquinolones are superior to erythromycin or clarithromycin for the treatment of *Legionella pneumonia* ^{78;79}. BTS guidelines recommended fluoroquinolones for severe LD ³². The addition of rifampicin is advised for immunocompromised patients or patients with severe pneumonia. Duration of the treatment is 8 – 14 days for non severe LD. Antibiotic therapy should be continued for 10 to 21 days in immunocompetent patients to decrease the rate of relapse⁸⁰.

Mycoplasma pneumoniae

Antimicrobial therapies with tetracycline, macrolide, or fluoroquinolone shorten the clinical course of clinical symptoms⁸⁰. Macrolides and tetracyclines are bacteriostatic against *M. pneumoniae*, whereas fluoroquinolones possess bactericidal activity^{81;82}

Azithromycin is recommended for 5 days while other macrolides such as clarithromycin and erythromycin, as well as tetracyclines and fluoroquinolones, usually require longer courses.

Corticosteroids may be beneficial in severe *M. pneumoniae* pneumonia⁸³⁻⁸⁵, but experience with this therapy is limited to case reports and small series. The recent published study by Miyashita et al⁸³. included 41 patients with refractory or severe *M. pneumoniae* pneumonia observed that the administration of steroids to patients with refractory and severe pneumonia resulted in the rapid improvement of symptoms and a decrease in serum LDH levels in all patients.

***Chlamydophila pneumoniae* and *Chlamydophila psittaci*:**

Antibiotic treatment for *C. pneumoniae* is very similar to *M. pneumoniae*. Therapy for two weeks with macrolides, tetracycline, doxycycline or fluoroquinolone is recommended^{80;86}. Azithromycin and clarithromycin are an alternative option to erythromycin for the tolerance. In case of patients with intolerance to macrolides or tetracyclines; fluoroquinolones such as levofloxacin or moxifloxacin are good alternatives.

***Coxiella burnetii*:**

Doxycycline is the treatment of choice for acute Q fever and two weeks of therapy is recommended for adults⁸. Doxycycline has been shown to result in a mean time to

defervescence of 2 to 3 days after the start of therapy⁸⁷. Levofloxacin or a macrolide are an alternative therapy.

Current recommendations from the CDC is to treat pregnant women with acute Q fever with co-trimoxazole up until the final 6 weeks of pregnancy, and to give doxycycline and hydroxychloroquine postpartum for 12 months to women who develop a serologic profile of chronic Q fever (Phase 1 IgG titer $\geq 1:1024$)^{88;89}. Because there is a risk for the fetus Doxycycline is contraindicated during pregnancy.

Reference List

1. File, T. M., Jr. and T. J. Marrie. 2010. Burden of community-acquired pneumonia in North American adults. *Postgrad.Med.* 122:130-141.
2. Niederman, M. S. 2007. Recent advances in community-acquired pneumonia: inpatient and outpatient. *Chest* 131:1205-1215.
3. Ewig, S., M. Woodhead, and A. Torres. 2011. Towards a sensible comprehension of severe community-acquired pneumonia. *Intensive Care Med.* 37:214-223.
4. Blasi, F. 2004. Atypical pathogens and respiratory tract infections. *Eur.Respir.J.* 24:171-181.
5. Cilloniz, C., S. Ewig, E. Polverino, M. A. Marcos, E. Prina, J. Sellares, M. Ferrer, M. Ortega, A. Gabarrus, J. Mensa, and A. Torres. 2012. Community-acquired pneumonia in outpatients: aetiology and outcomes. *Eur.Respir.J.* 40:931-938.
6. Dumke, R., C. Schnee, M. W. Pletz, J. Rupp, E. Jacobs, K. Sachse, and G. Rohde. 2015. *Mycoplasma pneumoniae* and *Chlamydia* spp. infection in community-acquired pneumonia, Germany, 2011-2012. *Emerg.Infect.Dis.* 21:426-434.
7. Marrie, T. J., N. Costain, S. B. La, W. Patrick, S. Forgie, Z. Xu, and S. A. McNeil. 2012. The role of atypical pathogens in community-acquired pneumonia. *Semin.Respir.Crit Care Med.* 33:244-256.

8. Basarab, M., M. B. Macrae, and C. M. Curtis. 2014. Atypical pneumonia. *Curr.Opin.Pulm.Med.* 20:247-251.
9. Brown, R. J., L. farlane-Smith, S. Phillips, and V. J. Chalker. 2015. Detection of macrolide resistant *Mycoplasma pneumoniae* in England, September 2014 to September 2015. *Euro.Surveill* 20.
10. Li, X., T. P. Atkinson, J. Hagood, C. Makris, L. B. Duffy, and K. B. Waites. 2009. Emerging macrolide resistance in *Mycoplasma pneumoniae* in children: detection and characterization of resistant isolates. *Pediatr.Infect.Dis.J.* 28:693-696.
11. Jain, S., W. H. Self, R. G. Wunderink, S. Fakhraan, R. Balk, A. M. Bramley, C. Reed, C. G. Grijalva, E. J. Anderson, D. M. Courtney, J. D. Chappell, C. Qi, E. M. Hart, F. Carroll, C. Trabue, H. K. Donnelly, D. J. Williams, Y. Zhu, S. R. Arnold, K. Ampofo, G. W. Waterer, M. Levine, S. Lindstrom, J. M. Winchell, J. M. Katz, D. Erdman, E. Schneider, L. A. Hicks, J. A. McCullers, A. T. Pavia, K. M. Edwards, and L. Finelli. 2015. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. *N.Engl.J Med.* 373:415-427.
12. Cilloniz, C., S. Ewig, E. Polverino, M. A. Marcos, C. Esquinas, A. Gabarrus, J. Mensa, and A. Torres. 2011. Microbial aetiology of community-acquired pneumonia and its relation to severity. *Thorax* 66:340-346.
13. Capelastegui, A., P. P. Espana, A. Bilbao, J. Gamazo, F. Medel, J. Salgado, I. Gorostiaga, M. J. Lopez de Goicoechea, I. Gorordo, C. Esteban, L. Altube, and J. M. Quintana. 2012. Etiology of community-acquired pneumonia in a

population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. *BMC.Infect.Dis.* 12:134.

14. Viasus, D., Y. S. Di, C. Garcia-Vidal, R. Verdaguer, F. Manresa, J. Dorca, F. Gudiol, and J. Carratala. 2013. Community-acquired *Legionella pneumophila* pneumonia: a single-center experience with 214 hospitalized sporadic cases over 15 years. *Medicine (Baltimore)* 92:51-60.
15. Arnold, F. W., J. T. Summersgill, A. S. Lajoie, P. Peyrani, T. J. Marrie, P. Rossi, F. Blasi, P. Fernandez, T. M. File, Jr., J. Rello, R. Menendez, L. Marzoratti, C. M. Luna, and J. A. Ramirez. 2007. A worldwide perspective of atypical pathogens in community-acquired pneumonia. *Am.J.Respir.Crit Care Med.* 175:1086-1093.
16. Cameron, R. L., K. G. Pollock, D. S. Lindsay, and E. Anderson. 2015. Comparison of *Legionella longbeachae* and *Legionella pneumophila* cases in Scotland; implications for diagnosis, treatment and public health response. *J.Med.Microbiol.*
17. Yu, V. L., J. F. Plouffe, M. C. Pastoris, J. E. Stout, M. Schousboe, A. Widmer, J. Summersgill, T. File, C. M. Heath, D. L. Paterson, and A. Chereshtsky. 2002. Distribution of *Legionella* species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. *J.Infect.Dis.* 186:127-128.
18. Whiley, H. and R. Bentham. 2011. *Legionella longbeachae* and legionellosis. *Emerg.Infect.Dis.* 17:579-583.

19. Carratala, J. and C. Garcia-Vidal. 2010. An update on Legionella. *Curr.Opin.Infect.Dis.* 23:152-157.
20. European Centre for Disease Prevention and Control. Legionnaires' disease surveillance in Europe, 2014. 2014.
Ref Type: Report
21. Woodhead, M. 2002. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. *Eur.Respir.J.Suppl* 36:20s-27s.
22. Marston, B. J., J. F. Plouffe, T. M. File, Jr., B. A. Hackman, S. J. Salstrom, H. B. Lipman, M. S. Kolczak, and R. F. Breiman. 1997. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. *Arch.Intern.Med.* 157:1709-1718.
23. Welte, T., A. Torres, and D. Nathwani. 2012. Clinical and economic burden of community-acquired pneumonia among adults in Europe. *Thorax* 67:71-79.
24. Haubitz, S., F. Hitz, L. Graedel, M. Batschwaroff, T. L. Wiemken, P. Peyrani, J. A. Ramirez, C. A. Fux, B. Mueller, and P. Schuetz. 2014. Ruling out Legionella in community-acquired pneumonia. *Am.J.Med.* 127:1010-1019.
25. Den Boer, J. W., J. Nijhof, and I. Friesema. 2006. Risk factors for sporadic community-acquired Legionnaires' disease. A 3-year national case-control study. *Public Health* 120:566-571.

26. Marston, B. J., H. B. Lipman, and R. F. Breiman. 1994. Surveillance for Legionnaires' disease: risk factors for morbidity and mortality. *Arch.Intern.Med.* 154:2417-2422.
27. Lanternier, F., F. Tubach, P. Ravaud, D. Salmon, P. Dellamonica, S. Bretagne, M. Couret, B. Bouvard, M. Debandt, I. Gueit, J. P. Gendre, J. Leone, N. Nicolas, D. Che, X. Mariette, and O. Lortholary. 2013. Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. *Chest* 144:990-998.
28. Greig, J. E., J. A. Carnie, G. F. Tallis, N. J. Ryan, A. G. Tan, I. R. Gordon, B. Zwolak, J. A. Leydon, C. S. Guest, and W. G. Hart. 2004. An outbreak of Legionnaires' disease at the Melbourne Aquarium, April 2000: investigation and case-control studies. *Med.J.Aust.* 180:566-572.
29. Farnham, A., L. Alleyne, D. Cimini, and S. Balter. 2014. Legionnaires' disease incidence and risk factors, New York, New York, USA, 2002-2011. *Emerg.Infect.Dis.* 20:1795-1802.
30. Jacobson, K. L., M. H. Miceli, J. J. Tarrand, and D. P. Kontoyiannis. 2008. Legionella pneumonia in cancer patients. *Medicine (Baltimore)* 87:152-159.
31. Pletz, M. W., G. Rohde, H. Schutte, R. Bals, B. H. von, and T. Welte. 2011. [Epidemiology and Aetiology of Community-acquired Pneumonia (CAP)]. *Dtsch.Med.Wochenschr.* 136:775-780.
32. Lim, W. S., S. V. Baudouin, R. C. George, A. T. Hill, C. Jamieson, J. Le, I. J. T. Macfarlane, R. C. Read, H. J. Roberts, M. L. Levy, M. Wani, and M. A.

- Woodhead. 2009. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax* 64 Suppl 3:iii1-55.
33. Waites, K. B. and D. F. Talkington. 2004. *Mycoplasma pneumoniae* and its role as a human pathogen. *Clin.Microbiol.Rev.* 17:697-728, table.
34. Atkinson, T. P., M. F. Balish, and K. B. Waites. 2008. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of *Mycoplasma pneumoniae* infections. *FEMS Microbiol.Rev.* 32:956-973.
35. Cilloniz, C., E. Polverino, S. Ewig, S. Aliberti, A. Gabarrus, R. Menendez, J. Mensa, F. Blasi, and A. Torres. 2013. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. *Chest* 144:999-1007.
36. Niederman, M. S., L. A. Mandell, A. Anzueto, J. B. Bass, W. A. Broughton, G. D. Campbell, N. Dean, T. File, M. J. Fine, P. A. Gross, F. Martinez, T. J. Marrie, J. F. Plouffe, J. Ramirez, G. A. Sarosi, A. Torres, R. Wilson, and V. L. Yu. 2001. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. *Am J Respir Crit Care Med* 163:1730-1754.
37. Miyashita, N., Y. Obase, K. Ouchi, K. Kawasaki, Y. Kawai, Y. Kobashi, and M. Oka. 2007. Clinical features of severe *Mycoplasma pneumoniae* pneumonia in adults admitted to an intensive care unit. *J.Med.Microbiol.* 56:1625-1629.
38. Izumikawa, K., K. Izumikawa, T. Takazono, K. Kosai, Y. Morinaga, S. Nakamura, S. Kurihara, Y. Imamura, T. Miyazaki, M. Tsukamoto, K. Yanagihara, K. Hara, and S. Kohno. 2014. Clinical features, risk factors

and treatment of fulminant *Mycoplasma pneumoniae* pneumonia: a review of the Japanese literature. *J.Infect.Chemother.* 20:181-185.

39. Sakai, T., T. Ishida, M. Arita, H. Tachibana, H. Yoshioka, M. Noyama, F. Tokioka, A. Ito, K. Furuta, A. Nishiyama, T. Hashimoto, H. Fujii, H. Nakajima, T. Kenri, and K. Shibayama. 2015. [A Study on the Clinical Course and Antimicrobial Susceptibility of *Mycoplasma pneumoniae* in a Community Hospital]. *Kansenshogaku Zasshi* 89:458-464.
40. Miyashita, N., T. Maruyama, T. Kobayashi, H. Kobayashi, O. Taguchi, Y. Kawai, T. Yamaguchi, K. Ouchi, and M. Oka. 2011. Community-acquired macrolide-resistant *Mycoplasma pneumoniae* pneumonia in patients more than 18 years of age. *J.Infect.Chemother.* 17:114-118.
41. Ewig, S. and A. Torres. 2003. Is *Chlamydia pneumoniae* an important pathogen in patients with community-acquired pneumonia? *Eur.Respir.J.* 21:741-742.
42. Chalmers, J. D., C. Rother, W. Salih, and S. Ewig. 2014. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. *Clin.Infect.Dis.* 58:330-339.
43. Blasi, F., P. Tarsia, and S. Aliberti. 2009. *Chlamydophila pneumoniae*. *Clin.Microbiol.Infect.* 15:29-35.
44. Knittler, M. R. and K. Sachse. 2015. *Chlamydia psittaci*: update on an underestimated zoonotic agent. *Pathog.Dis.* 73:1-15.

45. CDC. Case definitions for infectious conditions under public health surveillance.
National Notifiable Diseases Surveillance System, CDC. 2010.
Ref Type: Report
46. Angelakis, E. and D. Raoult. 2010. Q Fever. *Vet.Microbiol.* 140:297-309.
47. Marrie, T. J. and D. Raoult. 1997. Q fever--a review and issues for the next century. *Int.J.Antimicrob.Agents* 8:145-161.
48. Pebody, R. G., P. G. Wall, M. J. Ryan, and C. Fairley. 1996. Epidemiological features of *Coxiella burnetii* infection in England and Wales: 1984 to 1994. *Commun.Dis.Rep.CDR Rev.* 6:R128-R132.
49. Roest, H. I., R. C. Ruuls, J. J. Tilburg, M. H. Nabuurs-Franssen, C. H. Klaassen, P. Vellema, B. R. van den, D. Dercksen, W. Wouda, M. A. Spierenburg, A. N. van der Spek, R. Buijs, A. G. de Boer, P. T. Willemsen, and F. G. van Zijderveld. 2011. Molecular epidemiology of *Coxiella burnetii* from ruminants in Q fever outbreak, the Netherlands. *Emerg.Infect.Dis.* 17:668-675.
50. Dijkstra, F., H. W. van der, N. Wijers, B. Schimmer, A. Rietveld, C. J. Wijkmans, P. Vellema, and P. M. Schneeberger. 2012. The 2007-2010 Q fever epidemic in The Netherlands: characteristics of notified acute Q fever patients and the association with dairy goat farming. *FEMS Immunol.Med.Microbiol.* 64:3-12.

51. Dahlgren, F. S., D. L. Haberling, and J. H. McQuiston. 2015. Q fever is underestimated in the United States: a comparison of fatal Q fever cases from two national reporting systems. *Am.J.Trop.Med.Hyg.* 92:244-246.
52. Schack, M., S. Sachse, J. Rodel, D. Frangoulidis, M. W. Pletz, G. U. Rohde, E. Straube, and K. Boden. 2014. *Coxiella burnetii* (Q fever) as a cause of community-acquired pneumonia during the warm season in Germany. *Epidemiol.Infect.* 142:1905-1910.
53. Schimmer, B., S. R. Ter, M. Wegdam, L. Zuchner, B. A. de, P. M. Schneeberger, T. Veenstra, P. Vellema, and H. W. van der. 2010. The use of a geographic information system to identify a dairy goat farm as the most likely source of an urban Q-fever outbreak. *BMC.Infect.Dis.* 10:69.
54. Wielders, C. C., A. M. Wuister, V. de, V, M. G. de Jager-Leclercq, C. A. Groot, F. Dijkstra, A. B. van Gageldonk-Lafeber, J. P. van Leuken, P. C. Wever, H. W. van der, and P. M. Schneeberger. 2014. Characteristics of hospitalized acute Q fever patients during a large epidemic, The Netherlands. *PLoS.One.* 9:e91764.
55. Hartzell, J. D., R. N. Wood-Morris, L. J. Martinez, and R. F. Trotta. 2008. Q fever: epidemiology, diagnosis, and treatment. *Mayo Clin.Proc.* 83:574-579.
56. Cilloniz, C., S. Ewig, M. Ferrer, E. Polverino, A. Gabarrus, B. J. Puig de la, J. Mensa, and A. Torres. 2011. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. *Crit Care* 15:R209.

57. Correia, A. M., J. S. Ferreira, V. Borges, A. Nunes, B. Gomes, R. Capucho, J. Goncalves, D. M. Antunes, S. Almeida, A. Mendes, M. Guerreiro, D. A. Sampaio, L. Vieira, J. Machado, M. J. Simoes, P. Goncalves, and J. P. Gomes. 2016. Probable Person-to-Person Transmission of Legionnaires' Disease. *N.Engl.J.Med.* 374:497-498.
58. Nilsson, A. C., P. Bjorkman, C. Welinder-Olsson, A. Widell, and K. Persson. 2010. Clinical severity of *Mycoplasma pneumoniae* (MP) infection is associated with bacterial load in oropharyngeal secretions but not with MP genotype. *BMC.Infect.Dis.* 10:39.
59. Jiang, W., L. Qian, H. Liang, M. Tian, F. Liu, and D. Zhao. 2014. Relationships between the varied ciliated respiratory epithelium abnormalities and severity of *Mycoplasma pneumoniae* pneumonia. *Scand.J.Infect.Dis.* 46:486-492.
60. Kannan, T. R., D. Provenzano, J. R. Wright, and J. B. Baseman. 2005. Identification and characterization of human surfactant protein A binding protein of *Mycoplasma pneumoniae*. *Infect.Immun.* 73:2828-2834.
61. Hanada, S., M. Morozumi, Y. Takahashi, S. Mochizuki, T. Sato, S. Suzuki, H. Uruga, H. Takaya, A. Miyamoto, N. Morokawa, K. Ubukata, and K. Kishi. 2014. Community-acquired pneumonia caused by macrolide-resistant *Mycoplasma pneumoniae* in adults. *Intern.Med.* 53:1675-1678.
62. Cao, B., C. J. Zhao, Y. D. Yin, F. Zhao, S. F. Song, L. Bai, J. Z. Zhang, Y. M. Liu, Y. Y. Zhang, H. Wang, and C. Wang. 2010. High prevalence of macrolide resistance in *Mycoplasma pneumoniae* isolates from adult and

adolescent patients with respiratory tract infection in China. *Clin.Infect.Dis.* 51:189-194.

63. Narita, M. 2010. Pathogenesis of extrapulmonary manifestations of *Mycoplasma pneumoniae* infection with special reference to pneumonia. *J.Infect.Chemother.* 16:162-169.
64. Tanaka, H., M. Narita, S. Teramoto, T. Saikai, K. Oashi, T. Igarashi, and S. Abe. 2002. Role of interleukin-18 and T-helper type 1 cytokines in the development of *Mycoplasma pneumoniae* pneumonia in adults. *Chest* 121:1493-1497.
65. Marrie, T. J., R. W. Peeling, T. Reid, and C. E. De. 2003. Chlamydia species as a cause of community-acquired pneumonia in Canada. *Eur.Respir.J.* 21:779-784.
66. Dupuis, G., J. Petite, O. Peter, and M. Vouilloz. 1987. An important outbreak of human Q fever in a Swiss Alpine valley. *Int.J.Epidemiol.* 16:282-287.
67. Marrie, T. J. 1990. Q fever - a review. *Can.Vet.J.* 31:555-563.
68. Hackstadt, T. and J. C. Williams. 1981. Biochemical stratagem for obligate parasitism of eukaryotic cells by *Coxiella burnetii*. *Proc.Natl.Acad.Sci.U.S.A* 78:3240-3244.
69. Jarraud, S., G. Descours, C. Ginevra, G. Lina, and J. Etienne. 2013. Identification of legionella in clinical samples. *Methods Mol.Biol.* 954:27-56.

70. Cloud, J. L., K. C. Carroll, P. Pixton, M. Erali, and D. R. Hillyard. 2000.
Detection of *Legionella* species in respiratory specimens using PCR with
sequencing confirmation. *J.Clin.Microbiol.* 38:1709-1712.
71. Marrero, M. and D. Raoult. 1989. Centrifugation-shell vial technique for rapid
detection of Mediterranean spotted fever rickettsia in blood culture.
Am.J.Trop.Med.Hyg. 40:197-199.
72. Shimada, T., Y. Noguchi, J. L. Jackson, J. Miyashita, Y. Hayashino, T.
Kamiya, S. Yamazaki, T. Matsumura, and S. Fukuhara. 2009. Systematic
review and metaanalysis: urinary antigen tests for Legionellosis. *Chest*
136:1576-1585.
73. Welte, M., K. Jaton, M. Altwegg, R. Sahli, A. Wenger, and J. Bille. 2003.
Development of a multiplex real-time quantitative PCR assay to detect
Chlamydia pneumoniae, *Legionella pneumophila* and *Mycoplasma*
pneumoniae in respiratory tract secretions. *Diagn.Microbiol.Infect.Dis.*
45:85-95.
74. Stralin, K., A. Backman, H. Holmberg, H. Fredlund, and P. Olcen. 2005.
Design of a multiplex PCR for *Streptococcus pneumoniae*, *Haemophilus*
influenzae, *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* to be
used on sputum samples. *APMIS* 113:99-111.
75. Nomanpour, B., A. Ghodousi, T. Babaei, S. Jafari, and M. M. Feizabadi. 2012.
Single tube real time PCR for detection of *Streptococcus pneumoniae*,
Mycoplasma pneumoniae, *Chlamydia pneumoniae* and *Legionella*

pneumophila from clinical samples of CAP. *Acta Microbiol.Immunol.Hung.* 59:171-184.

76. Potts, A., M. Donaghy, M. Marley, R. Othieno, J. Stevenson, J. Hyland, K. G. Pollock, D. Lindsay, G. Edwards, M. F. Hanson, and K. O. Helgason. 2013. Cluster of Legionnaires disease cases caused by *Legionella longbeachae* serogroup 1, Scotland, August to September 2013. *Euro.Surveill* 18:20656.
77. Fenollar, F. and D. Raoult. 2004. Molecular genetic methods for the diagnosis of fastidious microorganisms. *APMIS* 112:785-807.
78. Dunbar, L. M., M. M. Khashab, J. B. Kahn, N. Zadeikis, J. X. Xiang, and A. M. Tennenberg. 2004. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. *Curr.Med.Res.Opin.* 20:555-563.
79. Garau, J., A. Fritsch, P. Arvis, and R. C. Read. 2010. Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by *Legionella* spp. *J.Chemother.* 22:264-266.
80. Bartlett, J. G., S. F. Dowell, L. A. Mandell, T. M. File Jr, D. M. Musher, and M. J. Fine. 2000. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. *Clin.Infect.Dis.* 31:347-382.
81. Waites, K. B., D. M. Crabb, and L. B. Duffy. 2003. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against *Mycoplasma pneumoniae*. *Int.J.Antimicrob.Agents* 21:574-577.

82. Bebear, C. M., H. Renaudin, A. Bryskier, and C. Bebear. 2000. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. *Antimicrob. Agents Chemother.* 44:1980-1982.
83. Miyashita, N., Y. Kawai, N. Inamura, T. Tanaka, H. Akaike, H. Teranishi, T. Wakabayashi, T. Nakano, K. Ouchi, and N. Okimoto. 2015. Setting a standard for the initiation of steroid therapy in refractory or severe *Mycoplasma pneumoniae* pneumonia in adolescents and adults. *J. Infect. Chemother.* 21:153-160.
84. Radisic, M., A. Torn, P. Gutierrez, H. A. Defranchi, and P. Pardo. 2000. Severe acute lung injury caused by *Mycoplasma pneumoniae*: potential role for steroid pulses in treatment. *Clin. Infect. Dis.* 31:1507-1511.
85. Tamura, A., K. Matsubara, T. Tanaka, H. Nigami, K. Yura, and T. Fukaya. 2008. Methylprednisolone pulse therapy for refractory *Mycoplasma pneumoniae* pneumonia in children. *J. Infect.* 57:223-228.
86. Monno, R., V. D. De, G. Losito, G. Sibilio, A. Costi, L. Fumarola, A. D'Aprile, and P. Marcuccio. 2002. *Chlamydia pneumoniae* in community-acquired pneumonia: seven years of experience. *J. Infect.* 45:135-138.
87. Sobradillo, V., R. Zalacain, A. Capelastegui, F. Uresandi, and J. Corral. 1992. Antibiotic treatment in pneumonia due to Q fever. *Thorax* 47:276-278.
88. Teunis, P. F., B. Schimmer, D. W. Notermans, A. C. Leenders, P. C. Wever, M. E. Kretzschmar, and P. M. Schneeberger. 2013. Time-course of antibody

responses against *Coxiella burnetii* following acute Q fever.

***Epidemiol.Infect.* 141:62-73.**

- 89. Anderson, A., H. Bijlmer, P. E. Fournier, S. Graves, J. Hartzell, G. J. Kersh, G. Limonard, T. J. Marrie, R. F. Massung, J. H. McQuiston, W. L. Nicholson, C. D. Paddock, and D. J. Sexton. 2013. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. *MMWR Recomm.Rep.* 62:1-30.**